Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04102774Not ApplicableCompleted

Effect of AIRVO Heated Humidification in Bronchiectasis

Role: collaborator

NCT04419441Unknown

Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma

Role: lead

NCT04454580Unknown

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Role: lead

NCT03339063Unknown

The Italian REgistry of Pulmonary Non-tuberculous mycobactEria

Role: collaborator

NCT02946476Completed

Prognostic Impact of Noncardiac Comorbidities in Heart Failure Patients

Role: lead

All 5 trials loaded